CytoGenix Receives Re-Supply Order for synDNA™
News Jun 14, 2006
The current order for synDNA™ was placed after the initial batch of synDNA™ proved to be the preferred material for use in the manufacture of innovative products by the client.
"The CytoGenix synDNA™ technology is ideally suited for many of our clients when conventional plasmid DNA is too costly or difficult to produce," stated Michael Chambers, President and CEO of Aldevron.
"The first order of synDNA™ met and exceeded our expectations in terms of quality, cost, and turn-around time."
"The relationship between CytoGenix and Aldevron continues to be mutually beneficial," said Malcolm Skolnick, President and CEO of CytoGenix.
"We are delighted to service clients by utilizing our excess production capacity thereby generating revenue to fund our internal product development programs."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE